John Powers, co-founder and President of Murrieta Genomics, LLC, the Southern California genomic sequencing business incubator, is pleased to announce that Gene Tox Lab Solutions, LLC has been accepted into the their incubator program.
Gene Tox CEO Catherine Rells noted a few of the benefits of joining Murrieta Genomics. “We had several conversations with the founders of Murrieta Genomics and realized that being able to access both science and business experience of not only the principals but the advisory board that they have assembled, would be quite advantageous. Also, we are not spending resources trying to build a lab and hire experts to develop our genomic panels. We anticipate an accelerated launch with Murrieta Genomics as a strategic partner.”
Gene Tox is working on providing solutions to assist healthcare organizations including hospitals and clinics manage their patient population through specialized lab testing, informatics and education, all while lowering healthcare costs and increasing revenue.
According to Ms. Rells, “It is estimated that half of all medical expenditures are squandered because of repeat procedures, the expenses associated with traditional methods of sharing information, delays in care, errors in care or delivery, and the like. We want to provide the solutions that can curb these costs. Incorporating health informatics reduces errors, increases communication, and drives efficiency.”
“By incorporating genomic sequencing data into patients’ records, doctors can have a clearer view into each patient’s risk factors – leading to more accurate identification, prevention and treatment recommendations,” stated Mr. Powers. “Our goal is to help Gene Tox develop the panels that can provide the kinds of insight that doctors need to achieve better outcomes – reducing the cost of care at the same time.”
About Gene Tox Lab Solutions, LLC
Gene Tox Lab Solutions mission is to improve patient care through providing quality lab testing services, optimal therapy, reducing traditional trial and error approaches to prescribing medication, reducing adverse drug reactions, improving the selection of drug targeting, and improving drug compliance while providing healthcare professionals with the first user-friendly reporting for genetic, toxicology and pharmacogenomic testing. The Company offers the first comprehensive, turnkey solution to genetic, pharmacogenomic, toxicology testing and data solution implementation through cutting edge testing abilities, customized service offerings, and industry-leading patient data interpretation solutions. For more information visit www.genetoxlabsolutions.com.
This post was written by mgjay